Dextroamphetamine Treatment for Comorbid Cocaine Dependence and ADHD

描述(由申请人提供)：此申请请求支持NIDA独立之路奖(K99 Roo)，使David Herin博士能够为研究药物滥用的药物治疗的独立研究生涯发展必要的技能。赫林博士拥有独特的经验和专业知识的结合，这将是他发展成为一名独立研究人员的巨大财富。申请者在Kathryn Cunningham博士那里接受的博士前培训确立了临床前神经药理学方面的明确专业知识。值得注意的是，他调查了药物治疗剂在啮齿动物身上阻断精神刺激剂的行为和生理影响的能力。他对翻译研究的兴趣使他在NIDA资助的药物开发单位(P50)获得了博士后奖学金，由John Grabowski博士领导，在那里，精心制定的博士后计划为Herin博士提供了临床研究许多方面的培训。拟议的多学科研究计划的指导部分为Herin博士提供了在药物使用障碍临床试验的开发、实施和分析方面获得更多专业知识的机会，包括一项考察右旋苯丙胺治疗患有可卡因依赖和注意力缺陷多动障碍(ADHD)的患者的能力的试点研究。此外，Herin博士将在这些研究的统计分析方面获得丰富的经验，并在持续的功能成像研究中与系教员合作。培训将通过具有临床试验设计、统计分析和功能成像专业知识的教员的授课和个性化指导来提供。这一多学科培训的最终结果将是实施一项大规模临床试验，评估右旋苯丙胺治疗多动症和可卡因依赖的疗效。总而言之，拟议中的培训将提供独特的、特殊的专业知识，使赫林博士能够做出重大的科学贡献，并在转化性药物滥用研究方面开始成功的职业生涯。

DESCRIPTION (provided by applicant): This application requests support for a NIDA Pathway to Independence award (K99 ROO) enabling David Herin, Ph.D, to develop the skills necessary for an independent research career investigating pharmacological treatments for substance abuse. Dr. Herin possesses a unique combination of experience and expertise that will be a tremendous asset as he develops into an independent researcher. The applicant's predoctoral training with Dr. Kathryn Cunningham established clear expertise in preclinical neuropharmacology. Notably, he investigated the ability of pharmacotherapeutic agents to block the behavioral and physiological effects of psychostimulants in rodents. His interest in translational research led him to pursue a postdoctoral fellowship in the NIDA-funded medication development unit (P50) led by Dr. John Grabowski, where a well formulated post-doctoral plan provided training for Dr. Herin in many facets of clinical research. The mentored portion of the proposed multidisciplinary research plan provides Dr. Herin with the opportunity to gain additional expertise in development, implementation, and analysis of substance use disorder clinical trials, including a pilot study examining the ability of dextroamphetamine to treat individuals with comorbid cocaine dependence and attention-deficit hyperactivity disorder (ADHD). In addition, Dr. Herin will obtain extensive experience in statistical analysis of these studies, and collaborate with department faculty in ongoing functional imaging studies. Training will be provided via didactic instruction and individualized guidance from faculty members with expertise in clinical trial design, statistical analysis, and functional imaging. This multidisciplinary training will culminate in implementation of a large scale clinical trial assessing the efficacy of dextroamphetamine to treat comorbid ADHD and cocaine dependence. In all, the proposed training will provide a unique, exceptional expertise that will permit Dr. Herin to make significant scientific contributions and embark on a successful career in translational drug abuse research.